Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study

The FDA will maintain its clinical hold on enrollment of new U.S. patients in Newron's Phase 3 ENIGMA-TRS 2 trial of evenamide, pending further written guidance and potentially additional protocol changes. Newron is expanding ENIGMA-TRS 2 enrollment across Europe, Asia and Latin America, where about 80 patients are in screening and at least 400 are targeted. ENIGMA-TRS 1 remains on track to enroll at least 600 patients by mid-October 2026, with 12-week topline data expected in Q1 2027; the continued U.S. hold creates regulatory and enrollment risk despite trials continuing internationally.

Analysis

The unresolved FDA process creates a valuation overhang that is larger than the near-term operational impact: a U.S. hold tied to a fatal event, even when investigators judge it unrelated, raises the probability of additional safety monitoring, protocol amendments, and a longer regulatory path. For a single-asset, late-stage CNS developer, the market is likely to apply a materially higher probability-of-failure discount until the agency's written rationale is disclosed. International enrollment can preserve the Q1 2027 readout timeline, but it does not eliminate the risk that FDA ultimately requires a separate U.S.-focused safety package before accepting global data for registration.

SUPN has only indirect exposure through its U.S. rights to Xadago, not evenamide, so this announcement should not change its earnings outlook or justify a trade. The more relevant second-order implication is for schizophrenia peers: a prolonged safety dispute would improve the relative strategic value of de-risked CNS assets and established antipsychotic franchises, while reducing prospective partnering leverage for Newron. The key catalyst is the FDA letter within weeks; a narrowly defined protocol request would likely reverse the initial risk discount, whereas a request for additional nonclinical work, adjudication of broader safety data, or a full clinical hold would shift the commercial timeline by quarters rather than weeks.

Key Decisions for Investors

• No directional position in SUPN or FCN on this development; neither has sufficiently direct economic exposure, and SUPN's Xadago royalty/franchise economics are not linked to evenamide.
• Place a watch alert on Newron (SIX: NWRN / XETRA: NP5) rather than buying an apparent dip: consider a small event-driven long only after the FDA letter confirms a finite protocol amendment and management reaffirms the Q1 2027 primary-endpoint timetable. Falsifier: any requirement for a new U.S. safety cohort, expanded cardiac monitoring, or a delay to the first pivotal readout.
• For investors with access to European equities, avoid treating continued non-U.S. enrollment as proof that the safety issue is resolved. Reassess after disclosure of the FDA's specific concern and updated cash runway; a funding need before pivotal data would compound regulatory-driven multiple compression.
• Monitor large-cap schizophrenia exposure, including Bristol Myers Squibb (BMY), for relative-value opportunities only if the FDA action broadens into a class-level glutamatergic safety concern; absent that, there is no read-through sufficient to support a sector pair trade.